{
  "report_rows": [
    {
      "kpi": "Q2 2026 Adjusted EPS",
      "prediction": "IN-LINE",
      "answer": "pred ~$1.28 vs. cons $1.28",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 Total Comparable Sales Growth (incl. full Exact Sciences comp)",
      "prediction": "IN-LINE",
      "answer": "pred ~9.8% vs. cons 9.85%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Diabetes Care / FreeStyle Libre (CGM) comparable sales growth",
      "prediction": "MISS",
      "answer": "pred ~8.5% vs. cons ~10.5% (mgmt had explicitly guided a return to double-digit growth)",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 comparable sales growth range",
      "prediction": "UNCHANGED",
      "answer": "guide ~6.5%-7.5% (reaffirmed, mid ~7.0%) vs. cons ~7.0% (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY2026 adjusted diluted EPS range",
      "prediction": "UNCHANGED",
      "answer": "guide ~$5.38-$5.58 (reaffirmed, mid $5.48) vs. cons ~$5.48 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q3 2026 adjusted EPS bridge/guide",
      "prediction": "LOWER",
      "answer": "guide ~$1.42-$1.48 vs. cons ~$1.47 (Q3 2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -2.2,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -4.0,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "Headline EPS/total comparable sales likely print in-line (mechanically supported by full Exact Sciences consolidation and reaffirmed FY guide), but the market's single most-scrutinized promise \u2014 CGM 'return to double-digit growth' in Q2 \u2014 is at high risk of missing given weakening U.S. Libre Rx trends and rising CGM competitive/pricing noise already cited in the July 14 sell-off. A miss there, layered on ongoing NEC/infant-formula litigation overhang and structural heart competitive concerns, gives sell-side analysts a concrete reason to trim out-quarter Diabetes Care and Nutrition estimates even if FY26 sales/EPS ranges are nominally reaffirmed \u2014 an implicit cut via mix/quality of growth rather than headline guidance. With the stock already down ~28% YTD and multiple consecutive down-legs tied to idiosyncratic (non-print) news, incremental negative revisions on CGM/litigation are more likely to compound over the following days (analysts publish updated models, price-target trims) than to reverse, supporting follow-through rather than a snap-back fade; only a clean double-digit CGM beat would flip this to a relief rally.",
  "day5_confidence": "MEDIUM"
}